Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost
Status:
Completed
Trial end date:
2017-10-06
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy and tolerability of a new formulation of latanoprost
without Benzalkonium Chloride (BAK-free). Patients with open-angle glaucoma who were using
BAK-containing latanoprost ophthalmic solution for ≥6 months, switched to BAK-free
latanoprost ophthalmic emulsion.